| rTOF patients (n = 58) | RV dilation patients (n = 28) | p | Normal controls (n = 12) | p |
---|---|---|---|---|---|
Demographics | |||||
 Age (years), IQR | 21.7 (12.2–29.6) | 11.5 (4.0–15.5) |  < 0.001 | 13.9 (9.1–17.7) | 0.038 |
 Female | 30 (51%) | 14 (50%) |  | 6 (50%) |  |
 BSA (m2) | 1.5 ± 0.40 | 1.2 ± 0.6 |  < 0.001 | 1.4 ± 0.5 | ns |
Native anatomy | |||||
 | TOF-PS 47 (84%) TOF-PA 11 (16%) | PAPVR 24 (85%) 2° ASD 4 (15%) |  |  |  |
CMR data | |||||
 RVEDV (mL) | 203 ± 81 | 165 ± 110 | ns | 131 ± 55 | 0.0017 |
 RVEDVI (mL/m2) | 131 ± 33 | 148 ± 57 | ns | 86 ± 15 |  < 0.001 |
 RVESVI (mL/m2) | 65 ± 21 | 61 ± 29 | ns | 38 ± 10 |  < 0.001 |
 RVEF (%) | 51.1% ± 5.5% | 60.4% ± 6.1% |  < 0.001 | 60.0% ± 5.8% |  < 0.001 |
 PR% | 27.9% ± 16.4% | 0.0 ± 0.04% |  < 0.001 | 0.0 ± 0.03% |  < 0.001 |
 Qp:Qs | 1.0 ± 0.05 | 2.5 ± 1.4 |  < 0.001 | 1.0 ± 0.08 | ns |